Clinical Report: T-knife Launches Phase 1 Trial of CRISPR T Cell Therapy

Overview

T-knife Therapeutics has received authorization to begin a Phase 1 clinical trial for TK-6302, a CRISPR-engineered T cell therapy targeting PRAME-expressing solid tumors. This first-in-human trial, authorized in Europe, aims to evaluate the therapy's efficacy in patients with advanced PRAME-positive cancers and is expected to begin later this year.

Background

The development of effective therapies for solid tumors remains a significant challenge in oncology, particularly due to the immunosuppressive tumor microenvironment. PRAME, a tumor-associated antigen expressed in various solid tumors such as squamous non-small cell lung, ovarian, endometrial, skin, and triple-negative breast cancers, makes it a promising target for T cell-based immunotherapies. The Phase 1 ATLAS trial represents a critical step in advancing engineered T cell therapies into solid tumor indications.

Data Highlights

No numerical data available from the source material.

Key Findings

• TK-6302 is designed to target PRAME, enhancing tumor recognition and cytotoxic activity.
• The therapy incorporates genetic modifications, including a high-affinity receptor targeting PRAME and a costimulatory CD8 coreceptor, to improve T cell persistence in the tumor microenvironment.
• Preclinical studies demonstrated sustained tumor cell killing and cytokine secretion in PRAME-expressing tumor models.
• Engineered T cells showed superior anti-tumor activity compared to control cells in three-dimensional tumor spheroid models.
• The ATLAS trial is the first to evaluate a CRISPR-engineered T cell therapy in humans targeting PRAME-positive solid tumors.

Clinical Implications

If successful, TK-6302 could significantly enhance treatment options for patients with advanced solid tumors, where current therapies are limited. The trial's outcomes may also inform future strategies for overcoming barriers in T cell therapy for solid tumors, particularly those related to the immunosuppressive tumor microenvironment.

Conclusion

The initiation of the Phase 1 ATLAS trial for TK-6302 marks a promising advancement in the application of CRISPR technology in oncology. This trial could pave the way for new therapeutic approaches targeting solid tumors.

References

1. T-knife Therapeutics, Source, 2023 -- T-knife Launches Phase 1 Trial of CRISPR T Cell Therapy
2. Dana-Farber, The Next Wave of Immune Cell Therapy, 2023
3. The ASCO Post, New Data on ALK Inhibitors and CAR T-Cell Therapies, 2023
4. The ASCO Post, CRISPR-Edited, Off-the-Shelf CAR T-Cell Therapy Shows Proof of Concept in Renal Cell Carcinoma, 2024
5. the asco post — CRISPR-Cas9-Edited TILs: Targeting Intracellular Immune Checkpoint CISH in Metastatic Colorectal Cancer
6. Uveal melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up - ScienceDirect
7. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial | Nature Medicine
8. Human Gene Therapy Products Incorporating Human Genome Editing | FDA